Skip to Main Content
An official website of the United States government
Epidemiology and Genomics Research Program

Erin M. Siegel, PhD, MPH

Associate Director
Office of the Associate Director,
Epidemiology and Genomics Research Program


  • PhD - Epidemiology (major), Cancer Biology (minor), University of Arizona
  • MPH - Epidemiology, University of Arizona
  • BS - Biochemistry, University of Arizona


Dr. Erin Siegel serves as Associate Director of the Epidemiology and Genomics Research Program (EGRP) for the National Cancer Institute's (NCI) Division of Cancer Control and Population Sciences (DCCPS). EGRP is the largest funder of cancer epidemiologic research worldwide; its focus is to support research in human populations to understand determinants of cancer occurrence and outcomes.

Prior to joining NCI in June 2024, Dr. Siegel was a Senior Member in the Departments of Cancer Epidemiology and Gastrointestinal Oncology at the Moffitt Cancer Center and Research Institute. She was also an Associate Professor in the Department of Oncologic Sciences in the University of South Florida’s College of Medicine. Dr. Siegel had an administrative leadership position as the inaugural Scientific Director of Moffitt’s Non-Therapeutic Research Office, a unique office dedicated to supporting the conduct of observational and cancer epidemiology studies.

Dr. Siegel has a wealth of experience building and leveraging patient cohorts and biorepositories to advance high-impact team science. She was a (Multiple) Principal Investigator of the ColoCare study, a large, multi-institutional, cohort study investigating outcomes among colorectal cancer patients, and established the Moffitt ColoCare Site in 2009. She was a co-investigator on several NIH research project grants (R01) that leveraged the infrastructure of the cohort to identify prognostic and predictive proteomic and metabolomic biomarkers of CRC recurrence, identify metabolomic and genomic predictors of cancer-related fatigue, and examine the association of body composition on CRC outcomes.

In addition, Dr. Siegel was instrumental in leading and providing strategic direction of Moffitt’s institutional biobanking protocol – the Total Cancer Care Protocol (TCC) – over 10 years and served as PI since 2021. She was an active collaborator, leveraging TCC resources for research spanning multiple cancers, including colorectal (CRC), lung, head and neck, kidney, and multiple myeloma. She has used multi-omics approaches to identify pan-cancer circulating biomarkers, including emerging biomarkers within exosomes, and has conducted molecular and clinical epidemiological studies focused on HPV-associated cervical, anal, and head and neck cancers.

Dr. Siegel’s recent scientific interests include cancer epidemiology and cancer survivorship research spanning lifestyle/behavioral factors, racial/ethnic disparities, and translational studies aimed at discovering and validating novel molecular, blood-based biomarkers related to the risk of adverse CRC outcomes.

Dr. Siegel has also been involved with and provided leadership to the Oncology Research Information Exchange Network (ORIEN) since 2014, most recently as its Steering Committee Chair. ORIEN is a national research network of 18 cancer centers in the United States that are focused on accelerating cancer research and advancing care through collaboration and partnerships.

Dr. Siegel serves on the Editorial Boards of Frontiers in Applied Genetic Epidemiology and Cancer Epidemiology, Biomarkers and Prevention and is a member of the American Association of Cancer Research, the American Society of Preventive Oncology, and the International Society for Biological and Environmental Repositories.

Select Publications

Dr. Siegel has published more than 110 peer-reviewed articles. See publications authored by Dr. Siegel in PubMed.